FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer. PMID 38869830 · Clin Cancer Res · 2024-Sep-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials. PMID 38837894 · Clin Cancer Res · 2024-Sep-03 The record describes a biomarker-correlative analysis of PIK3CA mutations pooled from four neoadjuvant trials. While the underlying trials are randomized and oncology-focused with drug interventions, this specific publication is a secondary analysis investigating predictive biomarkers for response (pCR) and exploratory survival, not a primary report of a definitive randomized trial's key efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Exercise and QUality Diet after Leukemia: A Randomized Weight Loss Trial among Adult Survivors of Childhood Leukemia in the Childhood Cancer Survivor Study. PMID 38652494 · Cancer Epidemiol Biomarkers Prev · 2024-Sep-03 The study is a randomized Phase III trial in oncology (childhood leukemia survivors) with original results, but it does not meet key eligibility criteria: it lacks a drug intervention (it tests a weight-loss intervention) and it lacks a time-to-event efficacy endpoint (the primary outcome is weight loss at 24 months, not survival or progression-free survival). |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Limited fasciectomy with versus without autologous adipose tissue grafting for treatment of Dupuytren's contracture (REMEDY): study protocol for a multicentre randomised controlled trial. PMID 39223657 · Trials · 2024-Sep-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| GnRH-a-based fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients: a multicenter, open-label, randomized designed clinical trial protocol. PMID 39223633 · Trials · 2024-Sep-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. PMID 39012717 · J Bone Miner Res · 2024-Sep-02 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial. PMID 40179340 · Clin J Am Soc Nephrol · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Post Hoc Analysis Comparing the Safety and Efficacy of PrabotulinumtoxinA in Millennials and Nonmillennials With Moderate to Severe Glabellar Lines. PMID 39196832 · Dermatol Surg · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial. PMID 39133474 · JAMA Neurol · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evidence from recent clinical trials in fibrotic interstitial lung diseases. PMID 39114938 · Curr Opin Pulm Med · 2024-Sep-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial. PMID 39088196 · JAMA Oncol · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial. PMID 39083288 · JAMA Dermatol · 2024-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The future of clinical trials in idiopathic pulmonary fibrosis. PMID 38963152 · Curr Opin Pulm Med · 2024-Sep-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. PMID 38958989 · JAMA Cardiol · 2024-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Preventive Effect of Neuromuscular Training on Chemotherapy-Induced Neuropathy: A Randomized Clinical Trial. PMID 38949824 · JAMA Intern Med · 2024-Sep-01 The record describes a randomized trial evaluating neuromuscular training to prevent chemotherapy-induced neuropathy in cancer patients receiving chemotherapy. While it is an oncology RCT with a drug-containing regimen and original results, it does not meet the core eligibility requirement of having a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR analysis. The primary endpoint is the incidence of a toxicity (neuropathy), making this a safety/supportive care study, not an efficacy trial for a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Erratum to "Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials". PMID 38848307 · Cancer · 2024-Sep-01 The record is a published erratum, not an original report of a trial's results. The title indicates it is an erratum to a previously published analysis focusing on surgical outcome as a prognostic factor in ovarian cancer, with no mention of a drug intervention or time-to-event efficacy endpoint in the abstract or metadata. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer. PMID 38833643 · J Clin Oncol · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Towards improved diagnosis: radiomics and quantitative biomarkers in 18 F-PSMA-1007 and 18 F-fluorocholine PET/CT for prostate cancer recurrence. PMID 38832429 · Nucl Med Commun · 2024-Sep-01 The study is an oncology RCT but lacks a time-to-event efficacy endpoint and does not test a drug-containing therapeutic intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial. PMID 38775550 · Int J Surg · 2024-Sep-01 The record meets most eligibility criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original result). However, it fails the 'phase3_or_definitive' criterion because the trial phase is not explicitly stated as Phase III, IIIb, or II/III in the provided metadata or abstract. The deterministic review also flags phase3 evidence as unclear. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies. PMID 38754125 · Rheumatology (Oxford) · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial. PMID 38630903 · Cancer · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy. PMID 38493901 · Int J Radiat Oncol Biol Phys · 2024-Sep-01 Eligible RCT in oncology but excluded because the primary endpoint is not a time-to-event efficacy endpoint and the intervention is non-drug (radiation therapy comparison). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3. PMID 38019088 · J Clin Gastroenterol · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study. PMID 37921522 · Cornea · 2024-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of Upadacitinib in Crohn's Disease: An Updated Systematic Review. PMID 39463627 · Cureus · 2024-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Mucosamin Spray as an Adjunct for Prevention of Oral Mucositis in Children under Chemotherapy: A Two-Center Randomized Clinical Trial. PMID 39371956 · J Dent (Shiraz) · 2024-Sep The study is an oncology RCT with a drug intervention and a time-to-event endpoint, but the publication metadata and abstract do not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. It is described as a 'randomized clinical trial' without phase specification, so the phase criterion cannot be confirmed. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension. PMID 39371627 · JACC Asia · 2024-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Angiotensin Receptor Neprilysin Inhibition: An Overlooked Frontier in the Treatment of Hypertension. PMID 39371626 · JACC Asia · 2024-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Role of Peripheral Parenteral Nutrition Composition on Clinical Outcomes in Patients Undergoing Gastrectomy or Colectomy: A Phase III Indian Clinical Trial. PMID 39360212 · Indian J Crit Care Med · 2024-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Translating efficacy of liver transplantation in liver-limited metastatic colorectal cancer into clinical practice: the TransMet trial. PMID 39341646 · ESMO Open · 2024-Sep The trial is randomized, human, oncological, and reports a time-to-event endpoint (OS). However, the primary intervention is liver transplantation (a surgical procedure), not a drug-containing intervention. The comparator is chemotherapy, but the trial is testing transplantation vs. chemotherapy, not a drug regimen. Therefore, it does not meet the drug-intervention criterion. Additionally, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided record. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer. PMID 39325020 · Cancer Med · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial. PMID 39324173 · Cancer Med · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD. PMID 39319046 · ERJ Open Res · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines. PMID 39318203 · J Med Virol · 2024-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre-clinical study. PMID 39315544 · Cancer Med · 2024-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long-Term Follow-Up of Patients with Advanced Colorectal Liver Metastasis: A Survival Analysis from the Randomized Controlled Multicenter Trial LIGRO. PMID 39310365 · Ann Surg Open · 2024-Sep The study is a randomized controlled trial (RCT) in oncology with a human population and a time-to-event efficacy endpoint (overall survival). However, it does not involve a drug-containing intervention (ALPPS and TSH are surgical procedures). The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and it cannot be assumed from the description. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second-line docetaxel: A randomized trial. PMID 39286738 · Health Sci Rep · 2024-Sep The study is a Phase II randomized trial, which does not meet the criterion of being a Phase III/IIIb or Phase II/III definitive trial. All other criteria (oncology, human, randomized, drug intervention, original result, time-to-event endpoints) are met, but the phase criterion is not satisfied. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Postoperative Management of Aneurysmal Subarachnoid Hemorrhage]. PMID 39285539 · No Shinkei Geka · 2024-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study. PMID 39282663 · JTO Clin Res Rep · 2024-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Inosine enhances the efficacy of immune-checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study. PMID 39267574 · Cancer Med · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214). PMID 39260162 · ESMO Open · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia. PMID 39259485 · Clin Pharmacokinet · 2024-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer. PMID 39254154 · Cancer Med · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension. PMID 39252867 · EClinicalMedicine · 2024-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study. PMID 39246719 · EClinicalMedicine · 2024-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations. PMID 39245991 · Mult Scler · 2024-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation. PMID 39243304 · Clin Pharmacokinet · 2024-Sep The study is a randomized phase III trial with a drug intervention in oncology, but the primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR reporting. Instead, it reports categorical response rates (major molecular response) at fixed timepoints, which does not meet the time-to-event criterion. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access? PMID 39232441 · ESMO Open · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). PMID 39227284 · Neurotherapeutics · 2024-Sep 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer. PMID 39225603 · Radiology · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |